HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Connect Biopharma Holdings (NASDAQ:CNTB) and maintained a price target of $8.
June 13, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating on Connect Biopharma Holdings (NASDAQ:CNTB) and maintained a price target of $8, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a price target at $8 by a reputable analyst suggests positive sentiment and confidence in the company's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100